Skip to main content

Table 4 Treatment of study patients during hospitalization

From: Factors affecting in-hospital mortality of non-tuberculous mycobacterial pulmonary disease

 

Total (%)

Death (%)

P-value

n = 16,192

n = 3166

Medications prescribed during hospitalization

 No use of NTM drugsa

7215

(44.6)

1504

(47.5)

< 0.001

 Erythromycin only

526

(3.2)

61

(1.9)

< 0.001

 RIF, EMB, CLR

1676

(10.4)

232

(7.3)

< 0.001

 RIF, EMB, CLR, +FQ and/or AG

778

(4.8)

188

(5.9)

0.001

 Corticosteroidsb

3383

(20.9)

1069

(33.8)

< 0.001

Treatment procedure

 Bronchial artery embolization

250

(1.5)

22

(0.7)

< 0.001

 Mechanical ventilation

1518

(9.4)

957

(30.2)

< 0.001

  1. aNTM drugs include the followings: rifampicin and rifabutin; ethambutol; isoniazid; macrolides, including clarithromycin and azithromycin; aminoglycosides, including streptomycin, kanamycin and amikacin; fluoroquinolones, including levofloxacin, moxifloxacin and sitafloxacin; and imipenem/cilastatin
  2. bCorticosteroids include those administered both orally and intravenously
  3. Abbreviations: AG aminoglycoside, CLR clarithromycin, EMB ethambutol, FQ fluoroquinolone, NTM non-tuberculous mycobacterial pulmonary disease, RIF rifampicin
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us